Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Outi Paija

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Medical Case Reports|June 29, 2011
Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: a case reportPia Vihinen, Outi Paija, Atte Kivisaari, et al.
Drugs in R&D|October 31, 2003
Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administrationRisto Huupponen, Outi Paija, Markku Salonen, et al.
Clinical Neuropharmacology|June 21, 2005
Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CROuti Paija, Kari Laine, Eeva-Riitta Kultalahti, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 27, 2010
Anaemia: a rare but neglected problem among Finnish patients receiving chemotherapy for solid tumoursPirkko-Liisa Kellokumpu-Lehtinen, Ulla Puistola, Outi Paija, et al.
Clinical Breast Cancer|October 22, 2011
Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trialAntonio Llombart, Antonio Frassoldati, Outi Paija, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2011
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trialHeikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, Riikka Huovinen, et al.
The Lancet. Oncology|November 13, 2009
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trialHeikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, Riikka Huovinen, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Medical Case Reports|June 29, 2011
Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: a case reportPia Vihinen, Outi Paija, Atte Kivisaari, et al.
Drugs in R&D|October 31, 2003
Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administrationRisto Huupponen, Outi Paija, Markku Salonen, et al.
Clinical Neuropharmacology|June 21, 2005
Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CROuti Paija, Kari Laine, Eeva-Riitta Kultalahti, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 27, 2010
Anaemia: a rare but neglected problem among Finnish patients receiving chemotherapy for solid tumoursPirkko-Liisa Kellokumpu-Lehtinen, Ulla Puistola, Outi Paija, et al.
Clinical Breast Cancer|October 22, 2011
Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trialAntonio Llombart, Antonio Frassoldati, Outi Paija, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2011
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trialHeikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, Riikka Huovinen, et al.
The Lancet. Oncology|November 13, 2009
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trialHeikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, Riikka Huovinen, et al.
Pageof 1